Adrenal Incidentaloma
17
6
7
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 17 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (17)
Serum and Salivary Cortisol Assessment in Patients With Adrenal Incidentalomas and Healthy Controls
Structured Evaluation of adRENal Tumors Discovered Incidentally - Prospectively Investigating the Testing Yield
Cardiovascular Complications After Adrenalectomy for Pheochromocytoma and Non-secreting Tumors
Clinical Outcome of Autonomous Cortisol Secretion in Adrenal Incidentalomas
Impact of Adrenal IncidenTalomas and Possible Autonomous Cortisol Secretion on Cardiovascular and Metabolic Alterations
CRISAL Study:Cancer Risk In Secreting Adrenal Lesions
Comparison of Imaging Quality Between Spectral Photon Counting Computed Tomography (SPCCT) and Dual Energy Computed Tomography (DECT)
The Prevalence and Characteristics of Adrenal Incidentaloma
Effect of Chronic Catecholamine Overproduction on Brown Adipose Tissue
Performances on Cognitive Functions and Brain Function and Follow-up After Different Treatments in Patients With Autonomous Cortisol Secretion: a Single-center, Prospective, Observational Study
Evaluation of New Diagnostic Indicator of Subclinical Hypercortisolism
China Adrenal Disease Registry
Association Between Stroke and Adrenal Incidentalomas
Effect of Surgical or Conservative Approach in Patients With Adrenal Incidentalomas
Morbidity and Mortality in Autonomous Cortisol Secretion
Natural History of NFAI: 10 Year Follow-up Results
A Prospective Cohort Study for Patients With Adrenal Diseases